← All trials
NCT03725267
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Jul 1, 2020
- Completion date
- Jul 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of Health Science of Porto AlegreLead sponsor
- Conselho Nacional de Desenvolvimento Científico e TecnológicoCollaborator
- Pontifical Catholic University of Rio Grande do SulCollaborator
- Federal University of Health Science of Porto AlegreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.